Activity of cisplatin in adenocarcinoma of the pancreas
作者： J.A. Wils , T. Kok , D.J.Th. Wagener , J. Selleslags , N. Duez
DOI: 10.1016/0959-8049(93)90175-F
关键词: Metastasis 、 Adenocarcinoma 、 Cisplatin 、 Oncology 、 Gastroenterology 、 Internal medicine 、 Pancreatic disease 、 Metastatic adenocarcinoma 、 Pancreatic cancer 、 Medicine 、 Pancreas
摘要: The activity of cisplatin in metastatic adenocarcinoma the pancreas was assessed 33 patients. Cisplatin administered a dose 100 mg/m2, every 4 weeks. There were 2 complete responses and 5 partial (a response rate 21%). median duration months (range, 2+ to 15 months). is modestly active drug advanced pancreatic cancer.
elsevier.com
sci-hub.se 参考文章(4)
C G Moertel, J Rubin, M J O'Connell, A J Schutt, H S Wieand, A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. Journal of Clinical Oncology. ,vol. 4, pp. 1053- 1057 ,(1986) , 10.1200/JCO.1986.4.7.1053
Santo Difino, Jimmie Harvey, James Ahlgren, John Fryer, Harvey Rothman, James E. Cantrell, Jacob Lokich, Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer. ,vol. 68, pp. 264- 268 ,(1991) , 10.1002/1097-0142(19910715)68:2<264::AID-CNCR2820680208>3.0.CO;2-5
J. B. Dougherty, D. Kelsen, N. Kemeny, G. Magill, J. Botet, D. Niedzwiecki, Advanced Pancreatic Cancer: A Phase I–II Trial of Cisplatin, High-Dose Cytarabine, and Caffeine Journal of the National Cancer Institute. ,vol. 81, pp. 1735- 1738 ,(1989) , 10.1093/JNCI/81.22.1735
A. Bowman, R.J. Fergussion, S.G. Allan, M.E. Stewart, A. Gregor, M.A. Combleet, A.P. Greening, G.K. Crompton, R.C.F. Leonard, J.F. Smyth, Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II study Annals of Oncology. ,vol. 1, pp. 351- 353 ,(1990) , 10.1093/OXFORDJOURNALS.ANNONC.A057773